The pharmaceutical industry has spent years discussing patient centricity. But a new reflection paper from the European Medicines Agency (EMA) suggests something much more significant is happening: Patient experience data (PED) is evolving from supportive information into a structured component of regulatory evidence.1
The EMA’s Reflection Paper on Patient Experience Data emphasizes the importance of systematically integrating the patient perspective throughout medicine development, regulatory assessment and post-marketing evaluation. Importantly, the document repeatedly highlights key themes such as data quality, methodological rigor, participant burden and patient-generated digital data.1 This shift signals a broader transformation in how regulators view information generated outside traditional site visits and clinical assessments.
But if patient experience data is expected to meet increasing standards of reliability and interpretability, what happens to data collection methods that still rely heavily on retrospective patient recall?
For decades, medication adherence in clinical trials has often been assessed using paper diaries, patient self-reporting or pill counts. While operationally simple, these approaches have significant scientific limitations. Multiple studies have shown that traditional self-reported adherence measures are vulnerable to recall bias, overreporting and “backfilling”, the practice of completing diaries retrospectively shortly before a site visit.2,3 In many studies, patients do not intentionally falsify data. Rather, retrospective reporting reflects the practical reality of daily life: people forget doses, forget timing details or complete missing entries from memory. The challenge is that subjective recall may no longer be sufficient in an environment where regulators increasingly expect patient-generated data to be reliable, traceable and fit for purpose.
This becomes especially important as decentralized and hybrid clinical trials continue to expand.4 When more activities occur remotely and outside direct site supervision, the integrity of home-generated patient data becomes increasingly critical for endpoint interpretation and regulatory confidence.
The EMA reflection paper explicitly recognizes patient-generated digital data as an important component of future evidence ecosystems.1 Medication-taking behavior should be viewed within this framework.How patients take medication at home, whether doses are delayed, missed, clustered or inconsistently timed, represents real-world patient behavior that directly influences treatment exposure, efficacy outcomes and safety interpretation.
Yet historically, much of this behavior has remained largely invisible.
Clinical trials frequently capture what was prescribed, but not necessarily what happened between visits. As regulators move toward more structured use of patient experience data, patient dosing behavior is likely to become increasingly important not only operationally, but scientifically.
Importantly, collecting this information does not necessarily require adding burden to participants. One of the central tensions highlighted in the EMA reflection paper is the balance between richer patient data collection and minimizing participant burden.1 This is where passive digital adherence technologies become particularly relevant.
Unlike traditional diaries that depend on manual reporting, passive electronic monitoring systems can capture dosing behavior automatically and continuously in the background. This allows researchers to generate objective, time-stamped adherence data without requiring patients to repeatedly complete questionnaires or reconstruct behavior from memory. From a regulatory and scientific perspective, this creates several advantages:
- improved data reliability,
- reduced recall bias,
- better visibility into real-world treatment exposure,
- greater interpretability of clinical outcomes.
At the same time, passive data collection aligns closely with broader industry trends toward digital health ecosystems, remote monitoring and patient-centered trial design.5
The EMA reflection paper does not explicitly focus on medication adherence technologies. But its direction is clear: patient-generated data used in medicine development will increasingly be expected to demonstrate methodological rigor, transparency and reliability.1 The future of patient-centric research will not depend solely on collecting more patient data.It will depend on collecting better patient data with minimal burden and maximum interpretability.
And this is precisely where reliable digital adherence ecosystems…
Establishing hard evidence for your trial…
AARDEX has a best practice methodology, independent of any device package or software platform. Utilising our expertise and experience in medication adherence and patient compliance we acquire, monitor, analyse, guide and interpret data to deliver absolute clarity and bring confidence to sponsors, trialists, and ultimately, patients.
AARDEX is the only mature, robust and proven adherence solution on the market today, one that maximises the reward, mitigates the risk and delivers resolution for your clinical trial. All delivered with the clarity, integrity and certainty you need to proceed with complete confidence in the exposure-response.
